Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.
about
Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis.Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease.Emerging Therapies for Inflammatory Bowel Disease
P2860
Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Biomarkers can predict potenti ...... n ulcerative colitis patients.
@ast
Biomarkers can predict potenti ...... n ulcerative colitis patients.
@en
type
label
Biomarkers can predict potenti ...... n ulcerative colitis patients.
@ast
Biomarkers can predict potenti ...... n ulcerative colitis patients.
@en
prefLabel
Biomarkers can predict potenti ...... n ulcerative colitis patients.
@ast
Biomarkers can predict potenti ...... n ulcerative colitis patients.
@en
P2093
P2860
P356
P1433
P1476
Biomarkers can predict potenti ...... n ulcerative colitis patients.
@en
P2093
Alexander W Gielen
Arezou Zargari
Eugen Musch
Nikolai V Kuznetsov
Oliver D von Stein
Petra von Stein
Ragnar Befrits
Robert Lofberg
P2860
P2888
P356
10.1186/1471-230X-14-79
P577
2014-04-23T00:00:00Z
P5875
P6179
1047232372